|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/04 | (2006.01) |
| C07D 401/14 | (2006.01) |
| (11) | Number of the document | 3880670 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19820938.9 |
| Date of filing the European patent application | 2019-11-15 | |
| (97) | Date of publication of the European application | 2021-09-22 |
| (45) | Date of publication and mention of the grant of the patent | 2023-06-07 |
| (46) | Date of publication of the claims translation | 2023-09-11 |
| (86) | Number | PCT/US2019/061815 |
| Date | 2019-11-15 |
| (87) | Number | WO 2020/102730 |
| Date | 2020-05-22 |
| (30) | Number | Date | Country code |
| 201862768802 P | 2018-11-16 | US |
| (72) |
PARSONS, Andrew Thomas , US
COCHRAN, Brian McNeil , US
POWAZINIK, IV, William , US
CAPORINI, Marc Anthony , US
|
| (73) |
Amgen Inc. ,
One Amgen Center Drive, Thousand Oaks, California 91320,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Pagrindinio tarpinio KRAS G12C inhibitoriaus junginio patobulinta sintezė |
| IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND |
| Payment date | Validity (years) | Amount | |
| 2024-10-22 | 6 | 139.00 EUR |
| 2025-11-15 |